MarginsXMarginsX
Home › Markets › Health Care › AIM

AIM ImmunoTech Inc. (AIM)

AIM trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.1310
-8.77% on the day
Market cap
$5.2M
Nano cap
Revenue · 2025
$88K
-48.2% on 2024
Net income · 2025
-$14.0M
-15861.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/0001493152-26-013301-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerAIM on NYSE
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryNot reported by the screener
IPO yearNot reported by the screener
SEC CIK0000946644

Financials · 2025

LineValue
Revenue$88K
Net income-$14.0M
Operating income-$11.7M
Net margin-15861.4%
Operating margin-13254.5%
Revenue growth-48.2%
Cash$3.0M
Total assets$5.8M
P/E (computed)Net income was not positive
P/S (computed)59.4×

Warning signs

Cash runway
6.8 months
$6.9M cash at September 30, 2026
Share count, 1 year
+1257.1%
2025-11-14 to 2026-11-11 · +7827.6% over 3 years
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$13K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements."
10-Q 2026-11-12
Cash and burn$6.9M cash; operating cash flow -$3.1M a quarter.Report 2026-09-30
Shares outstanding39,919,844 (2026-11-11); 2,853,114 a year earlier; 48,841,656 three years earlier. 1y figure adjusted for splits (1.031-for-1 overall); 3y figure adjusted for splits (1-for-96.993 overall).Cover page 2026-11-11
Reverse splits, 3 years1; latest 1-for-100 on 2025-06-12Source 2025-06-12
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 4 424B5 takedowns, 3 at the marketLatest 2026-06-10
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBDO USA, P.C., Miami, Florida, United StatesPCAOB Form AP 2026-03-30
Late filings, 12 months1 NT noticeNT 10-Q 2025-11-17
Insider trades, 12 monthsBought $13K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$22K-$3.1M-$2.9M$6.9M$1.4M$91K10-Q 2026-11-12
Q2 2026
2026-06-30
$26K-$3.8M-$4.6M$9.9M$3.6M$95K10-Q 2026-08-07
Q1 2026
2026-03-31
$22K-$3.0M-$2.7M$5.8M$4.2M$94K10-Q 2026-05-15
Q4 2025
2025-12-31
$21K-$4.2M-$2.0M$3.0M$4.5M$88K10-K 2026-03-27
Q3 2025
2025-09-30
$26K-$3.3M-$5.1M$2.3M$1.9M$112K10-Q 2025-11-17
Q2 2025
2025-06-30
$25K-$2.8M-$1.5M$476K$2.7M$121K10-Q 2026-08-07
Q1 2025
2025-03-31
$16K-$3.7M-$2.4M$898K$2.4M$146K10-Q 2026-05-15
Q4 2024
2024-12-31
$45K-$6.0M-$4.0M$1.7M$2.8M$170K10-K 2026-03-27

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-12.5%
1 month-17.6%
3 months-46.2%
Year to date-87.2%
1 year-90.2%
From 52-week high-90.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
SNTISenti Biosciences Holdings Inc.$0.1360-2.86%$5.2M
BTTCBlack Titan Corporation$0.2873-9.20%$4.3M
CRISCuris Inc.$0.4358-2.07%$4.1M
LIMNLiminatus Pharma Inc.$2.97-0.67%$4.0M
CELZCreative Medical Technology Holdings Inc.$0.5201-1.51%$4.0M
INABIN8bio Inc.$0.8160-0.49%$8.8M
TCRXTScan Therapeutics Inc.$0.1451-9.65%$9.2M
INTSIntensity Therapeutics Inc.$3.07-0.32%$10.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier